MedTrace Logo

The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

NCT04774107 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2022-08-30

No results posted yet for this study

Summary

Primary Objective:

To determine the P1101 pharmacokinetic (PK) profile at the single dose of 400 μg.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

P1101 + Ribavirin

P1101 400 µg SC

Sponsors & Collaborators

  • PharmaEssentia

    lead INDUSTRY

Principal Investigators

  • Huang Yi-Wen, MD/PhD · PharmaEssentia

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-26
Primary Completion
2022-07-18
Completion
2022-07-18

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04774107 on ClinicalTrials.gov